-
All Resources
(choose a category)
-
All Resources
-
selected
Evidence
Evidence, advice, guidance and standards
-
Improvement
Improvement and implementation support
-
Scrutiny
Assurance, scrutiny, measurement and reporting
-
-
Healthcare Area
- Dermatology
- Musculoskeletal system
-
Resource Type
- NICE Guidance
- Programme
- Year
- prev
- Page 14 of 3
25 results found filtered by Evidence Remove Evidence Filter Musculoskeletal system Remove Musculoskeletal system Filter NICE Guidance Remove NICE Guidance Filter Clear Search
-
NICE STA guidance no 280 - Rheumatoid arthritis (2nd line) - abatacept (rapid review of TA 234)
- Published
- 24 April 2013
- Cycle of Improvement
- Evidence
-
NICE STA guidance no 281 - Canakinumab for gout – terminated appraisal
- Published
- 24 April 2013
- Cycle of Improvement
- Evidence
-
NICE MTA Guidance no 279 - Percutaneous vertebroplasty and percutaneous balloon kyphoplasty
- Published
- 24 April 2013
- Cycle of Improvement
- Evidence
-
STA Guidance No 238 – Tocilizumab for the treatment of systemic juvenile idiopathic arthritis
- Published
- 14 December 2011
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 234 – abatacept for the treatment of rheumatoid arthritis
- Published
- 24 August 2011
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 233 – golimumab for the treatment of ankylosing spondylitis
- Published
- 24 August 2011
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 225
- Published
- 22 June 2011
- Cycle of Improvement
- Evidence
-
NICE Single Technology Appraisal Guidance No 220 Golimumab for the treatment of psoriatic arthritis
- Published
- 27 April 2011
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No. 204 Denosumab for the prevention of osteoporotic fractures
- Published
- 27 October 2010
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 195 – Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid
- Published
- 25 August 2010
- Cycle of Improvement
- Evidence